Upadacitinib Hemihydrate

CHEMBL5315119 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
778.8 g/mol
LogP
Phase
4

A hemihydrate form of upadacitinib with the same therapeutic properties. This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments.

الوزن الجزيئي

778,8000 g/mol

TPSA

158,00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O

InChI

InChI=1S/2C17H19F3N6O.H2O/c2*1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15;/h2*3-6,10-11,21H,2,7-9H2,1H3,(H,24,27);1H2/t2*10-,11+;/m11./s1

Molecular Formula

C34H40F6N12O3

HBD / HBA

5 / 13

الروابط القابلة للدوران

6

الذرات الثقيلة

55

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A hemihydrate form of upadacitinib with the same therapeutic properties. This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments.

Yes, Upadacitinib Hemihydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315119. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 133053456. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.